Aminotadalafil

Aminotadalafil is a structural analog of tadalafil — the only difference is a single N-amino substitution on the diketopiperazine ring of the pyrazino-pyrido-indole scaffold. That one-atom change preserves the (6R,12aR) stereochemistry and the binding geometry that makes the parent compound a potent phosphodiesterase type 5 (PDE5) inhibitor. The mechanism is therefore essentially the tadalafil mechanism, with the practical caveat that the human safety database is thinner.

PDE5 Inhibition and the NO / cGMP Axis#

PDE5 is the enzyme that hydrolyzes cyclic GMP — the second messenger downstream of nitric oxide / soluble guanylate cyclase signalling in vascular smooth muscle. When endothelial NO release activates guanylate cyclase, intracellular cGMP rises, protein kinase G fires, intracellular calcium drops, and smooth muscle relaxes. PDE5 terminates that signal by chewing up cGMP. Block PDE5 and the relaxation response is sustained, amplified, and prolonged.

Aminotadalafil binds the catalytic site of PDE5 with potency in the same low-nanomolar range as the parent. Structure-activity work in the piperazinedione series established that the N-position is one of the more permissive substitution sites — alkyl, amino, and acyl variants all retain potent inhibition.

"The SAR established that substitutions at the N-position of the diketopiperazine ring, including an N-amino substituent, are well tolerated and retain potent PDE5 inhibition." — Daugan A. et al., Journal of Medicinal Chemistry, 2003

The downstream effect is the same family of responses the bodybuilding and looksmaxxing community uses tadalafil for: cavernosal relaxation (erectile response), systemic vasodilation (BP reduction and training pump), pulmonary vasodilation, and prostatic / bladder-neck relaxation (BPH symptom relief).

Isoform Selectivity — Why No Blue-Tinted Vision#

There are eleven PDE isoforms in human tissue. Sildenafil and vardenafil cross-react meaningfully with PDE6 in the retina, which is the source of the transient blue-tinted-vision side effect those compounds are known for. The tadalafil scaffold — and aminotadalafil with it — is several orders of magnitude more selective for PDE5 over PDE6, which is why visual side effects are rare with this chemotype.

The trade-off is modest cross-reactivity with PDE11, an isoform expressed in skeletal muscle and pituitary tissue. This is the working hypothesis for the mild back / limb myalgia that 3–5% of subjects report on tadalafil — a class effect that extrapolates to aminotadalafil. It typically presents 12–24 hours post-dose, is dose-dependent, and resolves without intervention.

Long Half-Life and the "Steady-State Pump" Profile#

"The mean terminal half-life of tadalafil was approximately 17.5 hours, supporting once-daily or on-demand administration protocols recurrent in the community." — Forgue ST. et al., British Journal of Clinical Pharmacology, 2006

A ~17.5-hour terminal half-life is the longest in the PDE5i class — roughly four-fold sildenafil's. The structural basis for that long half-life (lipophilicity, slow hepatic clearance via CYP3A4, stable scaffold) is preserved in aminotadalafil, and the compound is treated as functionally equi-durable mg-for-mg in community practice.

Practically, this drives two distinct protocol modes:

The daily low-dose protocol is what underpins both the on-cycle BP / pump use case and the hair-stack adjunct use case. A continuous PDE5 block at low intensity gives sustained tonic vasodilation without the larger peak-trough swing of on-demand dosing — which is what most users running it alongside an AAS cycle or minoxidil/finasteride stack actually want.

"A daily low-dose regimen of tadalafil demonstrated robust efficacy and favorable compliance in erectile dysfunction, supporting its widespread adoption in continuous-use protocols." — Washington SL, Shindel AW., Drug Design, Development and Therapy, 2010

Microcirculatory Effects — Scalp, Skin, Muscle Pump#

PDE5 is expressed in cutaneous and scalp microvasculature, not just the corpus cavernosum. Chronic low-dose PDE5 inhibition increases dermal blood flow, and this is the mechanistic basis for stacking 2.5–5mg daily aminotadalafil with topical minoxidil and a 5α-reductase inhibitor in a hair-retention protocol. Improved follicular perfusion is the working theory for why daily PDE5i appears to augment minoxidil response in androgenetic alopecia.

The same vasodilatory effect drives the "pump" subjective response that physique-focused users notice during training on a daily low-dose protocol — especially in vascular muscle groups (delts, arms, calves). It is not anabolic in any meaningful sense — no nitrogen retention, no IGF-1 effect, no androgen receptor activity — but it does make working muscles look and feel fuller during a session and modestly improves perceived endurance by lowering peripheral vascular resistance.

Cardiovascular and BP Effects on Cycle#

Systemic vasodilation produces a 5–10 mmHg drop in systolic pressure in most subjects on daily low-dose PDE5i. For physique-focused users running aromatizing AAS or 19-nors — compounds that drive BP up via water retention, estrogen-mediated vascular tone, and altered RAAS signalling — that BP-shaving effect is the whole point. It does not replace a proper antihypertensive (telmisartan, nebivolol) at higher cycle pressures, but as a first-line on-cycle adjunct at 5mg daily it is one of the highest-leverage interventions in the community toolkit.

Hard contraindication — non-negotiable: PDE5 inhibitors must never be combined with nitrates (nitroglycerin, isosorbide mono/dinitrate), nitric-oxide donors including amyl/isobutyl nitrite ("poppers"), or soluble guanylate cyclase stimulators (riociguat). The mechanism is additive — both classes inflate the cGMP signal — and the combination produces severe, potentially fatal hypotension. A minimum 48-hour washout is required between the tadalafil-class scaffold and any nitrate exposure. This contraindication extends to aminotadalafil on mechanistic grounds and is not optional.

The Analog Caveat#

Aminotadalafil has never undergone formal clinical development. Every published dataset on the molecule itself is analytical — detection in adulterated sexual-enhancement products, structural characterization, mass-spec identification. There is no human PK study, no dose-finding study, and no long-term safety database.

"Aminotadalafil is among 80 designer analogs of PDE5 inhibitors reported worldwide in unregulated supplements, raising concerns about potency, purity, and unknown safety profiles." — Muschietti L. et al., Drug Testing and Analysis, 2020

The mechanism is well-characterized by extrapolation from the parent — the binding pocket, the cGMP axis, the half-life class, the receptor selectivity. What is not characterized is the metabolite profile, the long-term tolerability, or the lot-to-lot content accuracy of research-grade material. The literature supports treating aminotadalafil as mechanistically equivalent to tadalafil while recognizing that the safety dataset is one peer-reviewed cohort thick — not two decades and millions of subjects thick.

Common (most users)#

• Headache — the dominant complaint across the PDE5i class, reported in ~10–15% of subjects at 10–20mg tadalafil-equivalent. Hydration, caffeine moderation, and dropping to 2.5–5mg daily resolves it for most. Persistent headache past week two warrants a dose reduction rather than an analgesic stack.
• Facial flushing — mild, transient vasodilation. Tends to fade as steady state is reached on a daily low-dose protocol; on-demand 10–20mg doses produce the most noticeable flush.
• Nasal congestion — vasodilation of the nasal mucosa. Saline rinse, pseudoephedrine, or oxymetazoline spray sparingly; resolves on dose reduction.
• Dyspepsia / mild reflux — administering with a light meal (rather than fasted) softens this. Avoid pairing with high-fat meals only because they delay Tmax, not because absorption is impaired.
• Lower back and limb myalgia — a tadalafil-class signature, attributed to PDE11 cross-reactivity and presumed to extend to aminotadalafil given the shared scaffold. Typically dull, bilateral, and dose-dependent. Usually resolves within 12–24h; if persistent at 10mg, the dose is dropped to 5mg.
• Mild visual brightness or "color wash" — far less common than with sildenafil (PDE6 selectivity is the structural advantage), but possible. Resolves with the dose.

Uncommon (dose-dependent or individual)#

• Orthostatic dizziness / lightheadedness on standing — most often seen when stacked with alpha-blockers (tamsulosin, doxazosin) or telmisartan / nebivolol on cycle. Timing separation of 4+ hours between the PDE5i and the antihypertensive resolves it. Home BP cuff readings standing vs. seated catch this early.
• Transient hypotension — relevant in users already running on-cycle BP management. Weekly home BP for the first month catches it; the protocol calls for backing the antihypertensive down before backing the PDE5i down, since the PDE5i is doing useful vascular work.
• Prolonged erection (2–4h) — uncommon and self-limiting at standard doses. Becomes more probable above 20mg/day or when stacked with strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) that raise plasma exposure.
• Tinnitus — rare, usually transient. Persistent tinnitus is a stop signal pending ENT workup.
• Elevated liver enzymes — hepatic clearance is the elimination route, and research-chem aminotadalafil has no human safety database. A baseline and 8-week ALT/AST/GGT panel is the conservative practice, particularly when stacked with oral 17α-alkylated AAS.

Rare but serious#

• Priapism (>4h erection) — medical emergency. Cavernosal ischemia begins around the 4-hour mark; permanent erectile tissue damage is possible past 6 hours. Warning sign: an erection that persists, painful, with no relation to ongoing stimulation. Stop the compound, seek urgent care.
• Non-arteritic anterior ischemic optic neuropathy (NAION) — sudden, painless, usually unilateral vision loss. Risk is concentrated in users with the "crowded optic disc" anatomy, diabetes, hypertension, and smoking history. Any acute visual change is a stop signal.
• Sudden sensorineural hearing loss — rare, can be unilateral, may be accompanied by tinnitus or vertigo. Any acute hearing change is a stop signal pending audiology workup.
• Severe hypotension / syncope — almost exclusively seen with co-administration of nitrates, NO donors, or riociguat (see contraindications), or with a CYP3A4 inhibitor stack producing supratherapeutic exposure.

Hard contraindications#

These are non-negotiable. The lines do not get crossed.

• Nitrates and nitric-oxide donors. Nitroglycerin, isosorbide mono- and dinitrate, amyl nitrite ("poppers"), molsidomine, sodium nitroprusside. Co-administration produces precipitous, potentially fatal hypotension. A minimum 48-hour washout from a tadalafil-class PDE5i is required before any nitrate is given. This includes recreational popper use — the single most lethal interaction in this class, and it has killed people.
• Riociguat and other soluble guanylate cyclase stimulators. Same downstream cGMP pathway, same prohibition.
• Recent (within 90 days) myocardial infarction, unstable angina, severe arrhythmia, or NYHA class III–IV heart failure. The vasodilatory load is not appropriate over an unstable cardiac substrate.
• Severe hepatic impairment. Clearance is hepatic; exposure climbs unpredictably.
• Severe baseline hypotension (resting <90/50) or untreated severe hypertension (>170/100). Both ends of the BP curve are exclusion criteria — the first because additive hypotension is dangerous, the second because PDE5i alone is not BP therapy and masking uncontrolled hypertension is worse than addressing it.
• Retinitis pigmentosa and other genetic retinal dystrophies. PDE6 involvement in the retinal phototransduction cascade makes this population uniquely vulnerable even with the favorable PDE5:PDE6 selectivity ratio.

Gender, fertility, and PCT considerations#

Aminotadalafil is non-hormonal and HPTA-neutral. It does not suppress endogenous testosterone, does not aromatize, does not bind the androgen receptor, and requires no PCT. The compound is run continuously on-cycle, through PCT, and into cruise without an off-period.

Female protocols for vascular and BP effects typically run at 1.25–2.5mg equivalent — half the standard daily dose. There is no virilization risk and no menstrual-cycle interaction. Pregnancy data on aminotadalafil specifically is absent; the conservative position is that pregnancy and active conception attempts are not the right window for an unstudied research-grade analog when pharmaceutical tadalafil is the cleaner option for the same effect.

A final note specific to aminotadalafil rather than tadalafil: the human safety database does not exist. Tadalafil has been administered to millions of subjects across two decades; aminotadalafil has been characterized almost entirely in forensic chemistry contexts as an adulterant (Hadwiger et al., 2010; Fischer et al., 2023; Muschietti et al., 2020). The side-effect profile above is extrapolated from tadalafil on the basis of a shared scaffold, shared stereochemistry, and shared PDE5 binding mode (Daugan et al., 2003) — a reasonable extrapolation, but an extrapolation. Lot-to-lot assay variability is the practical compounding concern: the literature on adulterated products documents label-vs-content divergence of 50–200%, so a new source warrants starting at 2.5–5mg equivalent until the lot has been characterized.